WORCESTER, Mass., April 7, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has initiated the Phase III protocol in North America for its proprietary buccally-absorbed oral insulin spray product, Generex Oral-lyn(tm), with the commencement of patient screening. The first screening took place in late March in Texas. Other clinical sites participating in the study located in the United States are in Texas, Maryland, Minnesota and California, and in Canada in the province of Alberta.
